Sanjivani Paranteral Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/xza48isv4zo0qgf8zhcrmpg0.pdf

Key Takeaways


Joint Ventures: The Structural Growth Bet

Srivardhan Khemka: "The trial batches are now on. The machines are under the performance check and we are expecting the complete operation to begin by the month of June."

IV Market Structure & Competitive Moat

Ashwani Khemka: "We have an advantage because our plant is very near to the port which no plant in India is very near to the port. We are near to JNPT from our facility from Pune it is hardly 2.5 hours. Transportation cost plays a major role in this."

Product Portfolio & Profitability Dynamics

Ashwani Khemka: "Every product cannot be profitable. Some are profitable to the duration of the time, availability and shortages. Some are perennially new products, which has a profitability for first two, three years. And some are me-too products."

Operational Scale-Up & Regulatory Upgrades


Financials: Costs, Margins & Balance Sheet


Guidance & Commitments

CommitmentSpecificsTimeline
Prague JV commercial startComplete operations begin, revenue recognition startsJune (Q2 FY25)
Prague JV profit contributionINR2.5 to INR3 crores consolidated at PBT levelFull FY25
HAL JV plant operationalPlant commercializedEnd of Q3 FY25
HAL JV revenue contributionOne quarter of revenue at ~INR25 crores run-rate (80% utilization)Q4 FY25
Base business revenue growth20-25% growthFY25
Consolidated top lineAround INR90 crores (including one quarter of HAL)FY25
Consolidated bottom lineINR12 to INR13 crores (including Prague contribution)FY25
EBITDA marginStay at 17-18%FY25
Dehradun capacity utilizationRise to 65-70%Coming quarters and next financial year
Product additions15 to 20 new productsComing year
Capex (Dehradun + Navi Mumbai)INR6 to INR8 croresFY25
Tax rate25-26%FY25

Key Metrics

MetricQ4 FY24
Revenue₹12.86 cr, +58% YoY
EBITDA margin17.2%, vs 17.1% in Q4 FY23
Net profit₹1.26 cr, +26% YoY
PAT margin9.8%, vs 12.3% in Q4 FY23
Injectable segment revenue growth52.9% YoY
Oral segment revenue growth66.2% YoY
Nutraceuticals revenue growth137% YoY
Revenue mix30% domestic, 70% exports
Full-year FY24 revenue₹54.4 cr, +53% YoY
Full-year FY24 EBITDA₹8.76 cr, vs ₹6.19 cr in FY23
Total product count145 as of Mar 31, 2024; 15 new products added in FY24
New geographies entered in FY246
Dehradun plant capacity utilization40% to 45% currently, expected to reach 65%–70% in coming quarters
Active registrations~180, filing 15–20 every quarter
FY25 consolidated revenue guidance~₹90 cr top line, 20%–25% base business growth
FY25 consolidated bottom-line guidance₹12–13 cr, including Prague profit contribution of ₹2.5–3 cr
HAL JV FY25 revenue estimate₹20–25 cr for one quarter, ~18% EBITDA margin
Tax rate guidance for FY2525%–26%